Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Azelaprag in Older Adults
NCT06141889Phase 1Completed
- Sponsor
- BioAge Labs
- Start
- Nov 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azelaprag in obesity, muscle atrophy and Sarcopenia, sponsored by BioAge Labs. Primary endpoints: Area under the concentration-time curve from time zero to the last measurable concentration, Area under the concentration-time curve from time zero to 24 hours and 4 more. Started Nov 2023; status: completed.
02
Drugs
azelaprag
03
Conditions
obesitymuscle atrophySarcopenia
Beyond the preview
Go deeper on NCT06141889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141889.